BCMA is selectively induced at the time of plasma cell differentiation and is almost absent on immature and memory B cells (Avery et al., 2003; Chiu et al., 2007). The communication between BCMA and its ligand APRIL and BAFF is required for the maintenance of long-lived plasma cells (O'Connor et al., 2004; Peperzak et al., 2013).
BCMA is a perfect target for cancers of plasma cells as it is not present in other important organs. Dozens of BCMA-targeting therapies, such as antibody-drug conjugate, Bi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells are presently being created and tested clinically. Bluebird and Celgene’s bb2121 is leading the pack. A phase I multi-center clinical trial has established a striking 80% response rate in multiple myeloma patients. If these methods are effectively established, it will bring multiple myeloma patients a much-needed option beyond Elotuzumab (anti-SLAMF7) and Daratumumab (anti-CD38antibody).
The interactions between BAFF/APRIL and their receptors are selective. It should be noted that BCMA can interact with APRIL as well as BAFF (Bolkun et al., 2016). However, the affinity of APRIL-BCMA interaction is considerably higher when compared to BAFF-BCMA binding (Bossen and Schneider, 2006).
ACROBiosystems offers a wide-ranging panel of BCMA proteins, including the unique biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). The company also provides-BCMA related proteins, for example, BAFF and BAFFR proteins.
Figure 1. Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. No. BC7-H82F0) with a linear range of 0.12–1.95 ng/mL.
Figure 2. The purity of Human BCMA, His Tag (Cat. No. BCA-H522y) is greater than 93% as determined by SEC-HPLC.
ACROBiosystems provides a range of ready-to-use biotinylated proteins using their in-house developed labeling techniques, which offer high bioactivity and less batch-to-batch difference. Furthermore, they also provide FITC-labeled BCMA and BAFF proteins.
BCMA Product List
Other Relevant Products
Other Multiple Myeloma Targets
- Avery et al., 2004, J Clin Invest. 112, 286–297.
- Chiu et al., 2007, Blood 109, 729–739.
- O’Connor et al., 2004, J. Exp. Med. 199, 91–98.
- Peperzak et al., 2013, Nat. Immunol. 14, 290–297.
- Bolkun et al., 2016, J. Cancer 7, 1979–1983.
- Bossen and Schneider, 2006, Semin. Immunol. 18, 263–275.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
To respond to coronavirus pandemic, ACROBiosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits, including Spike-derived antigen S1, RBD and Nucleocapsid protein. Proteins have been supplied to diagnostic companies in large quantity.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.